Skip to main content

Distal Subungual Onychomycosis

3
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Moberg Pharma
Moberg PharmaSweden - Stockholm
3 programs
1
2
MOB015BPhase 31 trial
MOB015BPhase 31 trial
MOB015BPhase 21 trial
Active Trials
NCT01814020CompletedEst. Jul 2014
NCT02866032Completed452Est. Jun 2020
NCT02859519Completed365Est. Nov 2019
IQVIA
IQVIADURHAM, NC
1 program
BB2603-1PHASE_21 trial
Active Trials
NCT04188574Completed111Est. Jun 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Moberg PharmaMOB015B
Moberg PharmaMOB015B
IQVIABB2603-1
Moberg PharmaMOB015B

Clinical Trials (4)

Total enrollment: 928 patients across 4 trials

NCT02859519Moberg PharmaMOB015B

A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

Start: Oct 2016Est. completion: Nov 2019365 patients
Phase 3Completed
NCT02866032Moberg PharmaMOB015B

Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

Start: Sep 2016Est. completion: Jun 2020452 patients
Phase 3Completed
NCT04188574IQVIABB2603-1

A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail

Start: Mar 2021Est. completion: Jun 2023111 patients
Phase 2Completed
NCT01814020Moberg PharmaMOB015B

An Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

Start: Dec 2012Est. completion: Jul 2014
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.